EAST BRUNSWICK, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010 at 1:00 p.m. Eastern Time. The conference is being held at The Boston Marriott Copley Place.
Individuals can access a live webcast of the presentation through the investor relations section of the Company's web site www.savient.com. Following the live presentation, a replay of the webcast will be made available on the Company's web site for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
SVNT - G
SOURCE Savient PharmaceuticalsBack to top
|SOURCE Savient Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved